Y-mAbs Therapeutics initiated with a Buy at JonesResearch - TipRanks
YMAB Stock | USD 9.77 0.24 2.40% |
About 67% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Y-mAbs Therapeutics initiated with a Buy at JonesResearch TipRanks
Read at news.google.com
Y MAbs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Y MAbs is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
PASG | Passage Bio | 2.63 | ||||
PCVX | Vaxcyte | 0.69 | ||||
BDTX | Black Diamond | 0.79 | ||||
KRON | Kronos Bio | 1.96 | ||||
BLUE | Bluebird Bio | 2.56 | ||||
DAWN | Day One | 2.66 | ||||
MIRM | Mirum Pharmaceuticals | 3.05 | ||||
RVMD | Revolution Medicines | 3.23 | ||||
MRUS | Merus BV | 4.03 | ||||
ARQT | Arcutis Biotherapeutics | 4.07 | ||||
TVTX | Travere Therapeutics | 4.12 | ||||
SNDX | Syndax Pharmaceuticals | 5.34 | ||||
ERAS | Erasca | 5.40 | ||||
EWTX | Edgewise Therapeutics | 5.54 | ||||
LRMR | Larimar Therapeutics | 6.00 | ||||
GBIO | Generation Bio | 6.30 | ||||
CCCC | C4 Therapeutics | 8.28 | ||||
STRO | Sutro Biopharma | 10.20 | ||||
ZNTL | Zentalis Pharmaceuticals | 10.57 | ||||
MRSN | Mersana Therapeutics | 14.18 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |